Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Federal Anti-Kickback Statute and Beneficiary Inducements CMP
Key claim: HHS is soliciting public comment on whether safe harbor regulations under the Federal Anti-Kickback Statute and Beneficiary Inducements CMP should be modified to better accommodate remuneration provided to individuals participating in clinical trials.
Abstract
(Proposed Rule · Health and Human Services Department) This request for information seeks input from the public on whether any additions or modifications are needed to the safe harbor regulations under the Federal anti-kickback statute or the exceptions to the civil monetary penalty provision prohibiting inducements to beneficiaries (the “Beneficiary Inducements CMP”) for remuneration provided to individuals in connection with their participation in clinical trials.
Why this matters
The Anti-Kickback Statute and Beneficiary Inducements CMP set the boundaries for what payments, gifts, or reimbursements clinical trial sponsors and providers can offer participants without violating federal fraud-and-abuse law when Medicare or Medicaid coverage is involved. An RFI signals that HHS is weighing whether current safe harbors chill legitimate trial participation incentives (e.g., travel, lodging, stipends), and any resulting rule changes would directly affect trial recruitment practices and beneficiary out-of-pocket costs for research participation.